<DOC>
	<DOCNO>NCT02099539</DOCNO>
	<brief_summary>This Phase I/II , open-label , multi-center , competitive enrollment dose escalation study ALT-803 patient relapse refractory multiple myeloma .</brief_summary>
	<brief_title>QUILT-3.005 : A Study ALT-803 Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>The purpose study evaluate safety , determine Maximum Tolerated Dose ( MTD ) Minimum Efficacious Dose ( MED ) characterize immunogenicity pharmacokinetic profile ALT-803 treat patient . The effect ALT-803 peripheral absolute lymphocyte count white blood cell count , number phenotype peripheral blood T ( total subset ) NK cell evaluate . The anti-tumor response ALT-803 also assess trial .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<criteria>ENTRY CRITERIA : DISEASE CHARACTERISTICS : Confirmed diagnosis relapsed/refractory multiple myeloma treatment least two different previous regimen . Refractory disease define progressive disease therapy progression within 60 day therapy . Progressive disease define 25 % increase low response value specify test . Measurable disease define least one following : Serum Mprotein ≥ 1g/dL ( IgG , IgM ) 0.5 g/dL ( IgA ) Urine Mprotein ≥ 200mg/24hours Serum free light chain ≥ 10 mg/dL abnormal kappa/lambda ratio PRIOR/CONCURRENT THERAPY : No antimyeloma treatment within 14 day start study treatment . Must recover side effect prior treatment . PATIENT CHARACTERISTICS : Performance Status • ECOG 0 , 1 , 2 Bone Marrow Reserve Absolute neutrophil count ( AGC/ANC ) ≥ 1000/uL Platelets ≥ 30,000/uL Hemoglobin ≥ 8g/dL Absolute lymphocytes ≥ 800/uL Leukocytes ≥ 3,000/uL Renal Function • Glomerular Filtration Rate ( GFR ) &gt; 40mL/min Serum creatinine ≤ 1.5 X ULN Hepatic Function Total bilirubin ≤ 2.0 X ULN AST , ALT , ALP ≤ 3.0 X ULN , ≤ 5.0 X ULN ( liver metastasis exist ) No positive Hep C serology active Hep B infection Cardiovascular No congestive heart failure &lt; 6 month No unstable angina pectoris &lt; 6 month No myocardial infarction &lt; 6 month No history ventricular arrhythmia No history supraventricular arrhythmia No NYHA Class &gt; II CHF No mark baseline prolongation QT/QTc interval Pulmonary • Normal clinical assessment pulmonary function Other Negative serum pregnancy test female childbearing potential Women pregnant nursing Subjects , female male , reproductive potential must agree use effective contraceptive measure duration study No know autoimmune disease correct hypothyroidism No know prior organ allograft allogeneic transplantation Not HIV positive No history evidence uncontrollable CNS disease No psychiatric illness/social situation No illness opinion investigator would exclude subject participate study Must provide inform consent HIPPA authorization agree comply protocolspecified procedure followup evaluation No active systemic infection require parenteral antibiotic therapy No ongoing chronic systemic corticosteroid ( &gt; 10 mg daily prednisone equivalent ) use immunosuppressive therapy ( history mild asthma require therapy eligible ) . Inhaled topical steroid , adrenal replacement steroid dose ≤ 10 mg daily prednisone equivalent , permit absence active autoimmune disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>absolute lymphocyte count</keyword>
	<keyword>antitumor</keyword>
	<keyword>cancer</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>immunochemotherapy</keyword>
	<keyword>interleukin-15</keyword>
	<keyword>multiple myeloma</keyword>
	<keyword>NK cell</keyword>
	<keyword>refractory</keyword>
	<keyword>relapse</keyword>
	<keyword>T cell</keyword>
	<keyword>white blood cell count</keyword>
</DOC>